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Summary Between 1971 and 1988, 20 patients with previously undiagnosed non-Hodgkin's lymphoma
(NHL), of intermediate or high grade histology presented with extradural spinal cord compression. All had
decompressive surgery. The first treatment after surgery was chemotherapy in nine and radiotherapy in 11
patients. At presentation 15% were ambulant and this improved to 55% after surgery; urinary continence
improved from 30 to 80%. Mobility and sphincter control remained unchanged, regardless of subsequent
therapy. Chemotherapy as the initial treatment modality after surgery, either alone or in combination with
radiotherapy, did not jeopardise functional outcome. Mobility after surgery was an independent prognostic
factor for survival, when corrected for age and stage at presentation (P = 0.04). The treatment of intermediate
and high grade NHL presenting with spinal cord compression should be based on histology, extent of disease
and age, as with other sites of presentation, but should also take into consideration the prognostic importance
of post-surgical mobility.
Non-Hodgkin's lymphoma (NHL) presenting with spinal
cord compression (SCC) has traditionally been treated by
decompressive surgery followed by local radiotherapy
(Rubin, 1969; Mullins et al., 1971; Friedman et al., 1976;
Black, 1979; Rao et al., 1982). Localised treatment at the site
of cord compression after surgery, was considered to give the
best chance of local control and therefore the best functional
result.
Chemotherapy is the treatment of choice in advanced ag-
gressive histology NHL and also in localised presentations,
since it treats subclinical metastatic disease (Connors et al.,
1987; Horwich et al., 1988; Jones et al., 1989; Longo et al.,
1989). It would also be considered as the first treatment after
decompressive surgery, in NHL presenting with spinal cord
compression, provided the functional outcome was not
jeopardised.
We reviewed the results of therapy in patients presenting
with SCC due to previously undiagnosed NHL. All had
initial decompressive laminectomy followed by either
chemotherapy, radiotherapy or combined modality therapy.
Analysis by functional outcome as well as survival provides a
rational basis for treatment strategies in this unusual present-
ation of NHL.
Patients and methods
Between 1971 and 1988, 20 patients with extradural spinal
cord compression due to previously undiagnosed NHL were
referred to The Royal Marsden Hospital for further staging
and therapy. Histology was reviewed in all patients and was
of intermediate grade in 15 and high grade in five (NCI
Working Formulation, 1982). The level of cord compression
was assessed prior to surgery by myelography in all but one
patient, in whom the clinical level correlated with the verte-
bral collapse on plain X-ray.
Following surgery all patients underwent staging investiga-
tions which included baseline haematology and biochemistry,
chest X-ray, bone marrow examination and lymphography
(11 patients) and/or abdominal CT scan (11 patients).
Clinical stage (CS) was assigned according to the Ann Arbor
staging (Carbone et al., 1971).
Functional status was assessed retrospectively before
surgery, 1 week, and 1 and 6 months after decompressive
surgery. Mobility was defined on a three point scale as
follows: ambulant, able to walk with or without aid; paretic,
unable to walk, but retained some leg movements; paraplegic,
no leg movement. Sphincter function was defined as urinary
continence versus incontinence/retention and faecal con-
tinence versus incontinence/requiring manual evacuation.
The median follow-up of the 20 patients was 42 months
(15-163 months). They were aged 12-75 years (median 58
years) and ten were male and ten female. Thirteen had CS I
and II and seven CS III and IV disease. The compression
was in the thoracic cord in 15 patients, in the lumbar region
in four and the cervical spine in one patient.
All patients had decompressive surgery at a referring hos-
pital. This was followed by chemotherapy in nine, and by
radiotherapy in 11 patients. Three patients received
chemotherapy alone and six chemotherapy followed by
radiotherapy. Five patients received radiotherapy alone, and
in six radiotherapy was followed by chemotherapy.
Radiotherapy was delivered by a Cobalt unit or a 5MeV
linear accelerator to a dose of 30-45 Gy in 1.75-3.00Gy
fractions at spinal cord depth, usually by a direct posterior
field.
Eleven patients received anthracycline containing
chemotherapy (five CHOP, four BACOP, one MACOP-B
and one a weekly low dose regimen (WLD) (CHOP: cyclo-
phosphamide, adriamycin, vincristine and prednisolone.
BACOP: bleomycin, adriamycin, cyclophosphamide, vincris-
tine and prednisolone. MACOP-B: weekly regimen of
'BACOP' drugs plus methotrexate. WLD: weekly regimen of
bleomycin, vincristine, etoposide, mitozantrone and cyclo-
phosphamide) and four patients received other combinations.
Survival was assessed by an actuarial method from the
date of diagnosis. A stratified log-rank analysis was per-
formed which included histology, site of compression, age,
stage, and mobility after surgery (Peto et al., 1977).
The patient characteristics are shown in Table I.
Results
Functional status
Before surgery, three patients (15%) were ambulant, nine
paretic and eight paraplegic. Following decompressive
laminectomy mobility improved in ten patients and
deteriorated in one, with 11 patients (55%) fully ambulant.
Of 14 patients presenting with urinary incontinence, nine
achieved bladder control after surgery. Urinary continence
therefore improved from 30 to 80%. Only three patients were
faecally incontinent prior to surgery and none recovered: one
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patient developed faecal incontinence after surgery.
With subsequent treatment, functional status remained
unchanged regardless of the initial treatment modality
(Figures 1 and 2; bowel data not shown). The use of
chemotherapy first did not compromise the functional out-
come 1 and 6 months after surgery, and both mobility and
sphincter function did not deteriorate during further follow-
up in any patient. Functional outcome was not related to the
site of cord compression (data not shown). Functional status
prior to surgery was the major determinant of post treatment
mobility: while only two out of eight (25%) paraplegic
patients became mobile, seven out of nine (78%) patients
with paresis became ambulant (P = 0.06). Only one patient
deteriorated after surgery. Urinary sphincter control also
markedly improved from 30 to 80% following surgery. Only
one patient had deterioration of faecal continence.
Survival and disease control
The overall median survival of the 20 patients was 8 months
(Figure 3). The median survival of 13 patients with CS I and
II disease was 42 months compared to 5 months in those
with CS III and IV (P <0.42). The 5-year survival of
patients aged <50 years and those > 50 years was 63% and
17% respectively (P <.05).
Tumour histology (intermediate versus high grade) and the
level of cord compression were not significant determinants
of survival (data not shown).
Mobility after surgery was a significant prognostic factor
for survival (Figure 4). Ambulant patients had a median
survival of 104 months compared with a median survival of 6
months in patients who were paretic or paraplegic after
surgery (P <0.001). When corrected for age and stage at
presentation, mobility after surgery remained an independent
prognostic factor for survival (P = 0.004).
Two patients following chemotherapy and one after
radiotherapy, failed to achieve control of extradural disease
at the site of cord compression. Nine other patients relapsed;
none at the site of original cord compression.
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Discussion
Spinal cord compression is a rare presentation of NHL,
occurring in 0.1-3.3% of patients (Oviatt et al., 1982). It is
most commonly caused by extradural disease, either due to
an isolated deposit within the spinal canal or by extension
from an adjacent nodal mass or bone involvement. Less
commonly, NHL may arise subdurally or within the spinal
cord, and the disease may take on the behaviour of primary
cerebral lymphoma, recurring within the central nervous
system. All 20 patients in this study had extradural disease,
and this was of intermediate or high grade histology.
The treatment of NHL is based on prognostic indicators
such as histology, age and the extent of disease. Because of
the known radiation sensitivity of lymphoma, extradural
NHL has traditionally been treated by radiotherapy, either
alone or followed by chemotherapy after initial decompres-
sive surgery (Rubin, 1969; Mullins et al., 1971; Friedman et
al., 1976; Black, 1979; Rao, 1982). It was assumed that this
achieved the best local control, and prevented further spinal
cord damage.
Radiotherapy alone would clearly be an inappropriate
curative treatment for extensive disease where chemotherapy
is the treatment of choice (Horwich & Peckham, 1983; De
Vita et al., 1985). Although local radiotherapy has been the
main treatment modality in localised aggressive NHL, this is
associated with a high recurrence rate and poor overall sur-
vival (Sutcliffe et al., 1985; Kaminsky et al., 1986). Recent
studies have suggested an improved survival and tumour
control with initial chemotherapy combined with radio-
therapy (Connors et al., 1987; Horwich et al., 1988; Jones et
al., 1989; Longo et al., 1989). It would therefore be
reasonable to adopt the policy of initial chemotherapy in
appropriate patients presenting with spinal cord compression
provided this approach did not result in neurological
deterioration. On theoretical grounds, there is a high
likelihood of response to chemotherapy alone, particularly as
there is no problem of drug access at an extradural site. As
there is some uncertainty about the recovery of neurological
100-
5 80
o 60
-040
.0
20
L 20
2-
6 MO 0-
Figure 1 Overall outcome following treatment: bladder function.
|N = 20
T---
F- r- I- --r X
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Years since diagnosis
Chemotherapy Figure 3 NHL presenting with SCC: overall survival.
Paraplegic
E-OP 1 MO PRE-OP 11/
1 WK 6MO 1 WK
10
6 MO
Figure 4
surgery.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Years since diagnosis
NHL presenting with SCC: survival by mobility after
Figure 2 Overall outcome following treatment: mobility.
Radiotherapy
PRNON-HODGKIN'S LYMPHOMA 129
function with treatment other than radiotherapy, we reviewed
the functional outcome in relation to different treatment
modalities.
All 20 patients underwent surgical decompression which
resulted in good functional improvement: 50% of patients
with initial impairment improved their mobility. As in spinal
cord compression from other malignancy, the pre-treatment
functional status was the major determinant of functional
outcome (Black, 1979).
With subsequent therapy after surgery, there was no
change in mobility or sphincter control in any patient,
regardless of whether chemotherapy or radiotherapy was the
initial treatment modality. This is in keeping with other case
reports of spinal cord NHL treated with chemotherapy
(Irvine & Robertson, 1964; Oviatt et al., 1982; Pui et al.,
1985). The degree and frequency of functional recovery are
similar to those reported by Mullins et al. (1971).
The overall survival of our 20 patients is similar to those
reported for patients of similar histology at other nodal and
extranodal sites (Horwich & Peckham, 1983; De Vita et al.,
1985) although the small numbers of patients with a wide
range of prognostic factors preclude a direct comparison. We
were not able to demonstrate the prognostic significance of
stage at a statistically significant level because of the small
numbers of patients in each group. However, mobility after
surgery was a significant independent prognostic factor for
survival when corrected for age and stage. As most patients
with paraparesis and paraplegia after surgery died of recur-
rent lymphoma, persistent impairment of spinal cord func-
tion would seem to reflect a parameter of aggressive
biological behaviour of the disease in these patients.
Although the treatment administered followed the treat-
ment policies of the Royal Marsden Hospital throughout the
period of study, it is difficult to ascertain retrospectively the
rationale for the treatment choice in individual patients. It is
therefore not possible to provide clear guidelines on patient
management. We have demonstrated that the use of chemo-
therapy after decompressive surgery does not jeopardise func-
tional outcome. The choice of treatment should therefore be
based on the extent of disease, tumour histology, and age, as
in other sites. Mobility after surgery, which can be con-
sidered akin to performance status, is an independent prog-
nostic factor and should also be taken into account.
Following decompressive surgery, chemotherapy would be
the initial treatment of choice in most patients with
intermediate and high grade NHL, followed by radiotherapy
in localised presentations. This would treat subclinical meta-
stases and the timing of chemotherapy, preceding radio-
therapy would result in less normal tissue damage (Yarnold
et al., 1983). Such a treatment approach may, on present
evidence, achieve the best survival without jeopardising the
functional outcome.
The patients in this study were initially treated at the Atkinson
Morley's and National Hospitals, and we are grateful to our
neurosurgical colleagues for their collaboration. We are also very
grateful to D.F. Easton for statistical help. This work was supported
by grants from the Cancer Research Campaign and The Royal
Marsden Hospital.
References
BLACK, P. (1979). Spinal metastasis: current status and recom-
mended guidelines for management. Neurosurgery, 5, 726.
CARBONE, P.P., KAPLAN, H.S., MUSHOFF, K., SMITHERS, D.W. &
TUBIANA, M. (1971). Report of the committee on Hodgkin's
disease staging classification. Cancer Res., 31, 1860.
CONNORS, J.M., KLIMO, P., FAIRAY, R.t4. & YOSS, N. (1987). Brief
chemotherapy and involved field raiation therapy for limited
stage, histologically aggressive lymphoma. Ann. Intern. Med., 107,
25.
DEVITA, V.T., JAFFE, E.S. & HELLMAN, S. (1985). Hodgkin's disease
and the non-Hodgkin's lymphomas. In Cancer, Principles and
Practice of Oncology, DeVita, V.T., Hellman, S. & Rosenberg,
S.A. (eds). Lippincott: Philadelphia.
FRIEDMAN, M., KIM, T.H. & PANAHON, A.M. (1976). Spinal cord
compression in malignant lymphoma. Cancer, 37, 1485.
HORWICH, A., CATTON, C.N., QUIGLEY, M., EASTON, D.F. &
BRADA, M. (1988). The management of early-stage aggressive
non-Hodgkin's lymphoma. Haematol. Oncol., 6, 291.
HORWICH, A. & PECKHAM, M.J. (1983). Bad risk non-Hodgkin's
lymphomas. Semin. Haematol., 20, 35.
IRVINE, R.A. & ROBERTSON, W.B. (1964). Spinal cord compression
in the malignant lymphomas. Br. Med. J., i, 1354.
JONES, S.E., MILLER, T.P. & CONNORS, J.M. (1989). Long term
follow-up and analysis of prognostic factors for patients with
limited stage diffuse large cell lymphoma treated with initial
chemotherapy with or without adjuvant radiotherapy. J. Clin.
Oncol., 7, 1186.
KAMINSKY, M., COLEMAN, C.N., COLBY, T.V., COX, R.S. &
ROSENBERG, S.A. (1986). Factors predicting survival in adults
with stage I and II large cell lymphoma treated with primary
radiation therapy. Ann. Intern. Med., 104, 747.
LONGO, D.L., GLATSTEIN, E., DUFFEY, 1¢.L. & 7 others (1989).
Treatment of localised aggressive lymphomas with combination
chemotherapy followed by involved field radiation therapy. J.
Clin. Oncol., 7, 1295.
MULLINS, G.M., FLYNN, J.P.G., EL-MAHDI, A.M., MCQUEEN, J.D. &
OWENS, A.H. (1971). Malignant lymphoma of the spinal epidural
space. Ann. Intern. Med., 74, 416.
OVIATT, D.L., KIRSHNER, H.S. & STEIN, R.S. (1982). Successful
chemotherapeutic treatment of epidural compression in Non-
Hodgkin's lymphoma. Cancer, 49, 2446.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis of randomised clinical trials requiring prolonged observ-
ation of each patient. 2: Analysis and examples. Br. J. Cancer,
35, 1.
PUI, C.H., DAHL, G.V., HUSTU, H.O. & MURPHY, S.B. (1985).
Epidural spinal cord compression as the initial finding in child-
hood acute leukaemia and non-Hodgkin lymphoma. J. Paed.,
106, 788.
RAO, T.V., NARAYANASWAMY, K.S., SHANKAR, S.K. & DESH-
PANDE, D.H. (1982). 'Primary' spinal epidural lymphomas. A
clinico-pathological study. Acta Neurochirur., 62, 307.
RUBIN, P. (1969). Extradural spinal cord compression by tumour.
Radiology, 93, 1243.
SUTCLIFFE, S.B., GOSPODAROWICZ, M.K.,IBUSH, R.S. & 7 others
(1985). Role of radiation therapy in localised non-Hodgkin's
lymphoma. Radiother. Oncol., 4, 211.
THE NON-HODGKIN'S LYMPHOMA PATHOLOGIC CLASSIFICATION
PROJECT (1982). National Cancer Institute sponsored study of
classifications of non-Hodgkin's lymphomas. Summary and de-
scription of a Working Formulation fir clinical usage. Cancer,
49, 2112.
YARNOLD, J.R., HORWICH, A., DUCHESNE, G., WESTBROOK, K.,
GIBBS, J.R. & PECKHAM, M.J. (1983). Chemotherapy and
radiotherapy for advanced testicular non-seminoma. (1) The
influence of sequence and timing of drugs and radiation on the
appearance of normal tissue damage. Radiother. Oncol., 1, 91.